Ray Co

Ray Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Ray Co (228670.KQ) as of Nov 18, 2026 is 126.37. In the previous year, Cash Conversion Cycle (CCC) was 364.73 — a change of -65.35% (lower).

Cash Conversion Cycle

126.37

YoY

-65.35%

Last updated:

Cash Conversion Cycle (CCC) of Ray Co is 2025 126.37 . Cash Conversion Cycle (CCC) of Ray Co was 2024 364.73 . It decreases by -65.35% lower compared to the previous year.

The Ray Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
195.37 KRW
Jan 1, 2019
130.38 KRW
Jan 1, 2020
292.06 KRW
Jan 1, 2021
145.80 KRW
Jan 1, 2022
212.28 KRW
Jan 1, 2023
259.65 KRW
Jan 1, 2024
364.73 KRW
Jan 1, 2025
126.37 KRW
The Ray Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
126.37-65.35%
364.73+40.47%
259.65+22.31%
212.28+45.60%
145.80-50.08%
292.06+124.02%
130.38-33.27%
195.37-7.78%
211.84-10.05%
235.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ray Co Stock analysis

What does Ray Co do? Ray Co., Ltd. generates revenue through the manufacturing and sale of advanced technology medical devices, focusing on digital diagnostic systems and digital therapy solutions. The company produces dental radiography equipment such as x-ray systems and cone beam computed tomography (CBCT) systems, alongside 3D scanning, dental computer aided design (CAD), and 3D printers for prosthodontics, orthodontics, and implant surgery. Domestic and overseas markets purchase these products, with the company operating through subsidiaries to distribute its offerings globally. Digital diagnostic systems like dental radiography equipment and CBCT systems are sold to healthcare providers and dental clinics, while digital therapy solutions including 3D scanning and CAD systems target dental laboratories and surgical centers. The firm's product portfolio serves both domestic and international clients, leveraging its subsidiaries for global distribution channels. Ray Co., Ltd. emphasizes advanced technology in its medical device offerings, with digital therapy solutions such as 3D printers and CAD systems being key revenue drivers. The company's focus on dental-specific applications ensures targeted sales to specialized healthcare segments, including prosthodontics, orthodontics, and implant surgery practices. Ray Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ray Co stock

Cash Conversion Cycle (CCC) of Ray Co is 126.37 in 2025.

Cash Conversion Cycle (CCC) of Ray Co changed from 364.73 to 126.37, representing a -65.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Ray Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Ray Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Ray Co

All Key Metrics — Ray Co